MJosé Juan· @mjuanfi81 · X·· 2 days agoScore90
Body · original
🚨 #ESMO26 | KEYNOTE-866: A disappointing result in MIBC!
Perioperative pembrolizumab + neoadjuvant cisgem vs neoadjuvant cisgem+ perioperative placebo.
📈 Higher pCR: 44.4% vs 35.8%
❌ EFS: HR 0.88 (95% CI 0.71–1.10); not significant
⚠️ OS: HR 1.00 (95% CI 0.79–1.27)
@OncoAlert
873 views · 12 likes · 6 reposts · 1 reply
Conference abstracts
4735Omatched by Proffered paper 1: Genitourinary tumour, renal and urothelial
Perioperative pembrolizumab (pembro) or placebo (pbo) + neoadjuvant cisplatin (cis) and gemcitabine (gem) in participants (pts) with muscle-invasive bladder cancer (MIBC): the double-blind, phase 3 KEYNOTE-866 study
https://esmocongress.esmo.orgReplies in this thread
- Rodrigo Sanchez Roger@RodRogSan
@mjuanfi81 @OncoAlert 🎯entonces a quien intensificamos❓ y como❓
Source: MJosé Juan · x.com